【摘要】 特必夫定(telbivudine)是一种选择性抗乙型肝炎病毒新药,可快速且显著地抑制乙型肝炎病毒(HBV)复制,降低并发肝硬化甚至肝癌的几率。临床试验研究表明特必夫定能够有效且选择性地抑制人肝肿瘤细胞株中的HBV病毒,而不会对体内其他正常细胞产生不良影响,具有优干其他抗病毒药物的特性。在迄今为止的试验中,特必夫定显示了良好的安全性及有效性,且较拉米夫定有更强的抗病毒活性。现主要对特必夫定的药理作用机制、药动学、临床应用进展及前景等进行综述。更多还原

【Abstract】 Telbivudine is a new drug demonstrating marked antiviral activity against the hepatitis B virus (HBV) and shows favorable bioactivities in inhibition of the virus’ replication and expression and reduction of incidence of liver necrosis and liver cancer.Telbivudine with high selectivity for HBV existed in human liver tumor cells has demonstrated virtually no activity against other viruses or infectious patho- gens.Up to date,telbivudine has shown favorable safety and effectiveness in the clinical study and has no drug resistance to be found.The mechanism of pharmacology,pharmacokinetics,safety and recent advance in clinical trials of telbivudine are reviewed in this paper.更多还原